Find the most recent news about COVID-19 research conducted by our clinician scientists, researchers, innovators and faculty.
April 14, 2020 - The most severe COVID-19 patients may require intubation, which can put health care providers at risk. When seeking clinical alternatives to intubation, the innovative "helmet" offers a promising option.
EnMed Produces an N95 Alternative
March 26, 2020 - As cases of COVID-19 increased and the nation put out a call for PPE, Houston Methodist worked with its engineering partners at Texas A&M University to create a 3D-printed alternative to conventional N95 masks.
EnMed Collaborates on Inhaler Device
April 8, 2020 - Houston Methodist leveraged their EnMed collaboration with Texas A&M University to develop a 3D printed spacer that can be attached to an inhaler.
GeneOne Life Science and Houston Methodist to Develop a COVID-19 Vaccine
March 17, 2020 - Houston Methodist researchers are partnering with GeneOne Life Science Inc. to develop an RNA vaccine against COVID-19, the novel coronavirus that has caused a global pandemic.
April 16, 2020 - Early results encourage the clinical research team conducting clinical trials of Gilead Sciences’ antiviral drug Remdesivir. Methodist Hospital was the first clinical trial site in Houston to test the antiviral drug.
Plasma Therapy Proves Transformative August 14, 2020 - The first to receive FDA approval to offer convalescent plasma therapy—and the first to publish study results—Houston Methodist is leading medical research on treatments for COVID-19. For this Houston patient, the decision to participate in the research trial made all the difference.
Protoyping Protection: HMAC Aerosol Box
March 30, 2020 - Two Houston Methodist doctors develop an aerosol container to help minimize risk from expelled air during intubation.
First Plasma Therapy Fast-Tracked by FDA
March 28, 2020 - Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient.
Trials Aim to Calm Cytokine Storms
May 6, 2020 -  Patients with severe cases of COVID-19 often have a heightened immune response called a “cytokine storm.” To slow this process, Deepa Gotur, MD, studied medications used to treat autoimmune diseases in hopes of decreasing cytokine storms caused by the virus. Now she is enrolling patients in clinical trials.
FDA Fast-Tracks RLF-100 Trial for Treating ARDS June 24, 2020 - Jihad Georges Youssef, MD, professor of clinical medicine, Department of Medicine, and transplant pulmonologist, J.C. Walter Jr. Transplant Center, is leading a multi-center clinical trial fast-tracked by the FDA to test a treatment for acute lung injury and, specifically, acute respiratory distress syndrome (ARDS) associated with COVID-19.
Wong Participates in COVID-19 Consortium July 10, 2020 - Stephen T. Wong, PhD, John S. Dunn, Sr. Presidential Distinguished Chair in Biomedical Engineering, participated in an international COVID-19 consortium established to mine shared, secured information from COVID-19 patients across multiple institutions in the U.S., Europe, Middle East and Africa. Oxford University Press published an article in the Journal of the American Medical Informatics Association.
Antiviral Offers Outpatient Treatment Option July 27, 2020 - An antiviral drug, favipiravir, previously approved in Japan to treat influenza, is now under clinical investigation at Houston Methodist to treat the SARS-CoV-2 coronavirus. The Phase 2, multicenter, randomized trial is sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.
COVID-19 Brings Awareness of Health Disparities August 4, 2020 - The pandemic is bringing a new awareness of the social determinants of health—and possibly a new population health data set that reveals more about health inequities. Director of the Center for Outcomes Research Bita Kash, PhD, discusses the effects on hospital-community partnerships.
COVID-19 Antibody Cocktail
COVID-19 REGN-CoV2 Clinical Trial
October 2, 2020 - Medical director of critical care Faisal Masud, MD, and Houston Methodist Research Institute president and CEO Ed Jones are quoted in a Houston Chronicle front page story about recent COVID-19 treatments, including the use of an antibody cocktail, REGN-CoV2, currently in a clinical trial at Houston Methodist.